Allergies Cardiology Clinical Research Research 
Velocity Clinical Research
JANUARY 3, 2024
The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research.
Scienmag
DECEMBER 2, 2020
Research evaluates use of fibryga®, Octaplas™, and Octaplex® as investigational therapies PARAMUS, N.J.
Scienmag
DECEMBER 1, 2020
December 2, 2020) – Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use of high-dose Octagam® 10% [Immune Globulin Intravenous (Human)] […].
Expert insights. Personalized for you.
52 
Let's personalize your content